Loading clinical trials...
Loading clinical trials...
A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Conditions
Interventions
Eltrombopag olamine
Locations
34
United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Hradec Králové, Czechia
GSK Investigational Site
Olomouc, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Caen, France
GSK Investigational Site
Créteil, France
Start Date
May 1, 2010
Primary Completion Date
May 1, 2014
Completion Date
May 1, 2014
Last Updated
March 12, 2015
NCT01072162
NCT00442871
NCT01064336
NCT00424177
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions